Acadia Hit By Two Surprise Disappointments With Nuplazid
No Future For MDD, No Priority Review For Dementia
Executive Summary
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.